Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2009-10-23
pubmed:abstractText
Thrombolysis remains the main therapeutic strategy used in stroke, but with a limited use to only a part of stroke patients. A neuroprotective approach would be necessary with a double objective : (1) to serve as an add-on treatment with thrombolysis to improve safety and increase therapeutic window ; (2) to limit infarct area by delaying neuronal death. While numerous molecules failed in clinical trials in stroke, pharmacological development is on-going with pleiotropic drugs targeting both neuronal and vascular parts of neurovascular unit. Another approach targets the functional rehabilitation and the neurorepair using pharmacological ways or cell therapy.
pubmed:language
fre
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0767-0974
pubmed:author
pubmed:issnType
Print
pubmed:volume
25
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
847-54
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
[Cerebral ischaemia: tomorrow's therapeutic tracks].
pubmed:affiliation
EA1046, département de pharmacologie médicale, Institut de médecine prédictive et de recherche thérapeutique, Université Lille-Nord de France, Faculté de médecine, Centre hospitalier et universitaire de Lille, 2, avenue Oscar Lambret 59037 Lille Cedex, France. r-bordet@chru-lille.fr
pubmed:publicationType
Journal Article, English Abstract, Review